Ep. 288 Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle
And actually going back to digital pathology one more time, there are also a lot of pretty reliable algorithms for simple Gleason scoring, which I think, you know, obviously is not as exciting as a MMI type tool that predicts progression or some other oncologic outcome.
Ep. 288 Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle
I mean, exactly like you said it, it's considered currently an option for intermediate-risk patients, unlike low-risk, where active surveillance is clearly stated in our guidelines as the preferred option.
Ep. 288 Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle
Then in terms of active surveillance, I think it's important to counsel them on their risk of progression and just overall oncologic outcomes that they can get.
Ep. 288 Active Surveillance for Intermediate Risk Prostate Cancer with Dr. Claire de la Calle
And if they have any of those risk factors that we mentioned earlier that potentially makes them a borderline active surveillance patient, they really need to understand and